(Q35607862)

9 August 2017

1 reference

title

Selection of endpoints for heart failure clinical trials (English)

1 reference

9 August 2017

1 reference

Luisa Zanolla

1

1 reference

PubMed ID

14675849

9 August 2017

Piero Zardini

series ordinal

2

1 reference

9 August 2017

1 December 2003

1 reference

European Journal of Heart Failure

9 August 2017

1 reference

9 August 2017

5

1 reference

9 August 2017

6

1 reference

9 August 2017

717-723

1 reference

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Mode of death in chronic heart failure. A request and proposition for more accurate classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Pitfalls in the serial assessment of cardiac functional status. How a reduction in "ordinary" activity may reduce the apparent degree of cardiac compromise and give a misleading impression of improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Surrogates, semantics, and sensible public policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Explanatory and pragmatic attitudes in therapeutical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

What are pragmatic trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Carvedilol and the Food and Drug Administration approval process: an introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

The effect of digoxin on mortality and morbidity in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Relationship between exertional symptoms and functional capacity in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Exercise testing as outcome in congestive heart failure trials. Design considerations when interpreting results

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: practical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

Are surrogate markers adequate to assess cardiovascular disease drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1388-9842%2803%2900101-6

10.1016/S1388-9842(03)00101-6

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14675849